Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory

Abstract Background Dengue, chikungunya and zika infections occur in tropical and subtropical regions of the world. We describe the utilization of an in-house nucleic acid test (NAT) targeting all three viruses for febrile returning travelers in Alberta, Canada. Methods NAT was performed until 40 da...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saugata Choudhury, Raymond Tellier, Kevin Fonseca, Byron M. Berenger
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Arbovirus NAT Dengue Zika Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/590ce868845d4a5e89a8153c6ce62e8d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:590ce868845d4a5e89a8153c6ce62e8d
record_format	dspace
spelling	oai:doaj.org-article:590ce868845d4a5e89a8153c6ce62e8d2021-11-14T12:44:21ZExperience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory10.1186/s12879-021-06842-w1471-2334https://doaj.org/article/590ce868845d4a5e89a8153c6ce62e8d2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12879-021-06842-whttps://doaj.org/toc/1471-2334Abstract Background Dengue, chikungunya and zika infections occur in tropical and subtropical regions of the world. We describe the utilization of an in-house nucleic acid test (NAT) targeting all three viruses for febrile returning travelers in Alberta, Canada. Methods NAT was performed until 40 days from symptom onset or exposure due to the prolonged duration of zika virus RNA detection. From Sept 1, 2017 to August 31, 2019, 2552 specimens from 1932 patients were tested. Results Approximately 2% of patients tested were NAT positive for dengue virus (n = 42), chikungunya virus (n = 4), and zika virus (n = 1). The majority presented with fever, myalgia and rash. Regions with the most frequent travel included SouthEast Asia (68.5%), South America (25%) and the Caribbean (6.5%). Ct values were stronger (~ 1.5 logs) for patients within 1–3 days following onset of clinical symptoms than those presenting later. Nineteen patients had urine and plasma submitted; 5 were positive for both specimens and 2 were positive only for dengue virus in the urine. Also, Ct values were lower for plasma when compared to the corresponding urine. RNA was detected until 10 days and 5 days post-exposure in plasma and urine respectively for dengue virus. Conclusions Owing to dengue viremia detected beyond the conventional 7 days and low levels of circulating zika virus globally, a cutoff of 14 days from symptom onset to NAT is sufficient to diagnose acute cases. Inclusion of a zoonotic history form that collects appropriate clinical history results in improved test utilization.Saugata ChoudhuryRaymond TellierKevin FonsecaByron M. BerengerBMCarticleArbovirusNATDengueZikaInfectious and parasitic diseasesRC109-216ENBMC Infectious Diseases, Vol 21, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arbovirus NAT Dengue Zika Infectious and parasitic diseases RC109-216
spellingShingle	Arbovirus NAT Dengue Zika Infectious and parasitic diseases RC109-216 Saugata Choudhury Raymond Tellier Kevin Fonseca Byron M. Berenger Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory
description	Abstract Background Dengue, chikungunya and zika infections occur in tropical and subtropical regions of the world. We describe the utilization of an in-house nucleic acid test (NAT) targeting all three viruses for febrile returning travelers in Alberta, Canada. Methods NAT was performed until 40 days from symptom onset or exposure due to the prolonged duration of zika virus RNA detection. From Sept 1, 2017 to August 31, 2019, 2552 specimens from 1932 patients were tested. Results Approximately 2% of patients tested were NAT positive for dengue virus (n = 42), chikungunya virus (n = 4), and zika virus (n = 1). The majority presented with fever, myalgia and rash. Regions with the most frequent travel included SouthEast Asia (68.5%), South America (25%) and the Caribbean (6.5%). Ct values were stronger (~ 1.5 logs) for patients within 1–3 days following onset of clinical symptoms than those presenting later. Nineteen patients had urine and plasma submitted; 5 were positive for both specimens and 2 were positive only for dengue virus in the urine. Also, Ct values were lower for plasma when compared to the corresponding urine. RNA was detected until 10 days and 5 days post-exposure in plasma and urine respectively for dengue virus. Conclusions Owing to dengue viremia detected beyond the conventional 7 days and low levels of circulating zika virus globally, a cutoff of 14 days from symptom onset to NAT is sufficient to diagnose acute cases. Inclusion of a zoonotic history form that collects appropriate clinical history results in improved test utilization.
format	article
author	Saugata Choudhury Raymond Tellier Kevin Fonseca Byron M. Berenger
author_facet	Saugata Choudhury Raymond Tellier Kevin Fonseca Byron M. Berenger
author_sort	Saugata Choudhury
title	Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory
title_short	Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory
title_full	Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory
title_fullStr	Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory
title_full_unstemmed	Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory
title_sort	experience with a triplex arbovirus nucleic acid test (nat) at a canadian public health laboratory
publisher	BMC
publishDate	2021
url	https://doaj.org/article/590ce868845d4a5e89a8153c6ce62e8d
work_keys_str_mv	AT saugatachoudhury experiencewithatriplexarbovirusnucleicacidtestnatatacanadianpublichealthlaboratory AT raymondtellier experiencewithatriplexarbovirusnucleicacidtestnatatacanadianpublichealthlaboratory AT kevinfonseca experiencewithatriplexarbovirusnucleicacidtestnatatacanadianpublichealthlaboratory AT byronmberenger experiencewithatriplexarbovirusnucleicacidtestnatatacanadianpublichealthlaboratory
_version_	1718429048957304832

Experience with a triplex arbovirus nucleic acid test (NAT) at a Canadian Public Health Laboratory

Ejemplares similares